Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Nov;71(11):e31286.
doi: 10.1002/pbc.31286. Epub 2024 Aug 16.

Venetoclax for pediatric patients with newly diagnosed acute myeloid leukemia

Amber Gibson  1 , Samantha Dickson  1 , David McCall  1 , Miriam Garcia  1 , Jeremy Connors  1 , Jiasen He  1 , Michael Roth  1 , Cesar Nunez  1 , Branko Cuglievan  1
Affiliations

Venetoclax for pediatric patients with newly diagnosed acute myeloid leukemia

Amber Gibson et al. Pediatr Blood Cancer. 2024 Nov.

Abstract

This retrospective study at the University of Texas MD Anderson Cancer Center evaluated frontline venetoclax combination therapy in 11 pediatric/adolescent patients with acute myeloid leukemia (AML). Despite the small sample size and retrospective nature, the treatment demonstrated safety and potential efficacy, with most patients achieving early complete remission. Adverse events were consistent with other AML therapies, and no discontinuations due to toxicity occurred. While acknowledging study limitations, including selection bias and diverse concurrent therapies, this research underscores the promising role of venetoclax in pediatric AML. Further investigation is crucial to validate its long-term efficacy in this population.

Keywords: acute myeloid leukemia; pediatric; venetoclax.

PubMed Disclaimer

References

REFERENCES

    1. Bolouri H, Farrar JE. The molecular landscape of pediatric acute myeloid leukemia reveals recurrent structural alterations and age‐specific mutational interactions. Nat Med. 2018;24(1):103‐112. doi:10.1038/nm.4439
    1. Aplenc R, Meshinchi S, Sung L, et al. Bortezomib with standard chemotherapy for children with acute myeloid leukemia does not improve treatment outcomes: a report from the Children's Oncology Group. Haematologica. 2020;105(7):1879‐1886. doi:10.3324/haematol.2019.220962
    1. Burnett AK, Russell NH, Hills RK, et al. Defining the optimal total number of chemotherapy courses in younger patients with acute myeloid leukemia: a comparison of three versus four courses. J Clin Oncol. 2021;39(8):890‐901. doi:10.1200/jco.20.01170
    1. Gamis AS, Alonzo TA, Meshinchi S, et al. Gemtuzumab ozogamicin in children and adolescents with de novo acute myeloid leukemia improves event‐free survival by reducing relapse risk: results from the randomized phase III Children's Oncology Group trial AAML0531. J Clin Oncol. 2014;32(27):3021‐3032. doi:10.1200/jco.2014.55.3628
    1. Creutzig U, Kutny MA, Barr R, Schlenk RF, Ribeiro RC. Acute myelogenous leukemia in adolescents and young adults. Pediatr Blood Cancer. 2018;65(9):e27089. doi:10.1002/pbc.27089

MeSH terms

LinkOut - more resources